Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Compass Therapeutics, Inc.

NASDAQ: CMPX · Life Sciences · 3 alerts · CIK 1738021

Share price
$0.6615Close, Nov 16
Market cap
$119M
Shares outstanding
180.09MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Compass Therapeutics, Inc. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Financial Results

Compass Therapeutics Financial Results

Compass Therapeutics reported Q3 2026 financial results, ending the period with $163 million in cash and marketable securities, which is expected to fund operations into 2028. The company is currently preparing for a BLA submission for tovecimig in biliary tract cancer (BTC) and plans to engage the FDA regarding the necessity of additional survival studies.

Term
Q3 2026

“The third quarter was a period of sustained execution across our pipeline. We continue to prepare the BLA submission for tovecimig and are working to engage the FDA to bring this important therapy to patients with BTC as quickly as possible. The full COMPANION-002 results, now published in the Journal of Clinical Oncology and presented at ESMO, highlight the strength of the supportive data for tovecimig.”

Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors

“We are confident in the role tovecimig can play in the biliary tract cancer treatment landscape. We are committed to bringing tovecimig to patients as quickly as possible and the totality of the tovecimig data reinforces the urgency of our engagement with the FDA to define the most efficient path to a BLA submission.”

Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.